Anal Carcinoma

P=N/A, N=8000, Not yet recruiting, First Affiliated Hospital of Kunming Medical University; First Affiliated Hospital of Kunming Medical University

P=N/A, N=300, Not yet recruiting, Fudan University

P1, N=15, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Oct 2024 | Trial primary completion date: Jul 2025 --> Oct 2024

P=N/A, N=360, Recruiting, Cedars-Sinai Medical Center | Trial primary completion date: Jun 2025 --> Jan 2026

P2, N=77, Completed, University of Washington | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Mar 2024

P=N/A, N=100, Not yet recruiting, University of California, San Francisco

P=N/A, N=409, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Apr 2024 --> Apr 2026

Additionally, HDAC6 and DNMT3B are emerging as important therapeutic targets for cancer. This study lays the foundation for further exploration of the oncogenic mechanisms of HPV E6/E7 and may provide new directions for the treatment of HPV-related cancers.

P2, N=192, Active, not recruiting, MacroGenics | Trial primary completion date: Feb 2025 --> Jul 2024

P1, N=105, Terminated, Incyte Corporation | Trial completion date: Jun 2026 --> Aug 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Aug 2024; A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.

P=N/A, N=60, Not yet recruiting, Tata Memorial Centre

P=N/A; N=500; Not yet recruiting; Sponsor:Lisa Flowers

P=N/A, N=33, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting

The addition of immunotherapy to CRT may be an effective first-line treatment option with favourable survival outcomes and acceptable toxicity for patients with ASCC. A prospective, randomized trial assessing the efficacy of CRT combined with a PD-1 inhibitor in patients with locally advanced ASCC is in progress.

Transgenic K14E6/E7 mice with established high-grade anal dysplasia were treated topically at the anus with the protease inhibitor saquinavir (SQV) in the setting of CD4+ T-cell depletion to mimic immunodeficiency...The CD4-depleted mice treated with DMBA had significantly increased tumor-free survival and overall survival as well as decreased tumor-volume growth over time when treated with SQV. These data suggest that topical SQV, in the setting of CD4 depletion and high-grade anal dysplasia, can increase tumor-free and overall survival; thus, it may represent a viable topical therapy to decrease the risk of progression of anal dysplasia to anal cancer.

P3, N=205, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting

P1, N=95, Terminated, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Aug 2024 | Active, not recruiting --> Terminated; Inadequate accrual rate

P1, N=95, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Sep 2025 | Trial primary completion date: Aug 2024 --> May 2024

The association between higher BMI and increased HIF-1α expression may provide insights into the interplay between metabolic health and tumor biology in ASCC. Further studies with larger cohorts are needed to validate these findings and explore targeted therapies focusing on HIF-1α modulation.

P3, N=600, Recruiting, Sahlgrenska University Hospital, Sweden | Trial primary completion date: Dec 2023 --> Oct 2024

P1, N=200, Active, not recruiting, SOTIO Biotech AG | Trial primary completion date: Aug 2024 --> Dec 2024

P2, N=192, Active, not recruiting, MacroGenics | N=382 --> 192 | Trial completion date: May 2027 --> Feb 2025 | Trial primary completion date: May 2027 --> Feb 2025

We will go into great depth regarding the diagnostic challenges in this instance and provide an outline of our approach. The immunohistochemical and prognostic importance of this case will also be covered.

The recurrence of superficial angiomyxoma is previously described, but in our case no signs of recurrence were seen in follow-up for a period of 6 months. Superficial angiomyxoma should be considered as differential diagnosis with other polypoid or nodular masses in anal canal.

With dose reduction in heterozygous patients, toxicity was within the range of patients without DPYD variants. Our clinical data suggest that dose-adapted 5‑FU-/capecitabine-chemoradiotherapy regimens can be safely considered in patients with heterozygous clinically relevant DPYD variants, but that the optimal dosage still needs to be determined to avoid both increased toxicity and undertreatment in a curative setting.

P=N/A, N=33, Not yet recruiting, Washington University School of Medicine

nHPV vaccine in adult WLHIV is immunogenic and safe.

Immunohistochemistry confirmed positivity for p63, CK5/6, and BCL2. Respect the treatment, due to the involvement of the anal sphincteric muscle, radiotherapy was chosen.

Clinical questions are arising regarding the role of immunotherapy in the adjuvant/perioperative setting, optimal timing of surgery in patients who respond to immunotherapy, and toxicities specific to patients with gastrointestinal malignancies. We outline the current landscape and future horizon of immunotherapy in gastrointestinal cancers, such as strategies to increase effectiveness of checkpoint blockade through combinations with other checkpoint inhibitors, cytotoxic chemotherapy, targeted agents, radiotherapy, CAR-T therapy, and cancer vaccines.

DNA methylation markers could be valuable in identifying high-risk HPV infections in oral samples and detecting potential precancerous lesions in anal samples. These markers may enhance the early detection and prevention strategies for HPV-related cancers in high-risk populations, with follow-up data indicating potential for monitoring lesion progression.

P=N/A, N=516, Completed, ANRS, Emerging Infectious Diseases | Active, not recruiting --> Completed

P2, N=23, Recruiting, Dustin Deming | Not yet recruiting --> Recruiting

P=N/A, N=300, Not yet recruiting, University of Pecs

P=N/A, N=314, Active, not recruiting, Aarhus University Hospital | Recruiting --> Active, not recruiting | N=600 --> 314 | Trial primary completion date: Apr 2026 --> Apr 2025

P=N/A, N=400, Recruiting, Aarhus University Hospital | Not yet recruiting --> Recruiting | Phase classification: P2 --> PN/A

P=N/A, N=200, Not yet recruiting, Case Comprehensive Cancer Center | Initiation date: Jul 2024 --> Feb 2025

P2, N=71, Active, not recruiting, Centre Francois Baclesse | Trial completion date: Dec 2023 --> Dec 2024

P=N/A, N=100, Recruiting, University of New South Wales Sydney, NSW, Australia | Not yet recruiting --> Recruiting

P1, N=18, Recruiting, The Affiliated Hospital of Qingdao University

P=N/A, N=40, Recruiting, Assiut University | Not yet recruiting --> Recruiting | Trial completion date: Aug 2024 --> Jan 2025 | Trial primary completion date: Jun 2024 --> Dec 2024

P2, N=130, Recruiting, Duke University | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025

A nadir CD4 count threshold below 350 cells per μL, particularly less than 200 cells per μL, has the potential to identify people with HIV at heightened risk of developing anal cancer. Customised screening strategies that prioritise screening for individuals at high risk with this surrogate marker could maximise available resources. External validation of these data with other cohorts is required before screening recommendations can be updated.